Truqap (capivasertib)
Indications for Prior Authorization
Truqap (capivasertib)
-
For diagnosis of Breast Cancer
Indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.
Criteria
Truqap
Prior Authorization (Initial Authorization)
Length of Approval: 12 Month(s)
- Diagnosis of breast cancer AND
- Disease is one of the following:
- Locally advanced
- Metastatic
- Will be taken in combination with fulvestrant AND
- Disease is hormone receptor (HR)-positive AND
- Disease is human epidermal growth factor receptor 2 (HER2)-negative AND
- Patient has one or more PIK3CA/AKT1/PTEN-alterations as detected by a U.S. Food and Drug Administration (FDA)-approved test or a test performed at a facility approved by Clinical Laboratory Improvement Amendments (CLIA) AND
- One of the following:
- Following progression on at least one endocrine-based regimen in the metastatic setting (e.g., anastrozole, letrozole, exemestane, tamoxifen, etc). OR
- Recurrence on or within 12 months of completing adjuvant therapy (e.g., chemotherapy)
Truqap
Prior Authorization (Reauthorization)
Length of Approval: 12 Month(s)
- Patient does not show evidence of progressive disease while on therapy
P & T Revisions
2025-02-04, 2024-11-26, 2024-01-18, 2024-01-03
References
- Truqap Prescribing Information. AstraZeneca Pharmaceuticals LP. Wilmington, DE. November 2023.
Revision History
- 2025-02-04: Annual review: No criteria changes.
- 2024-11-26: Added new 160mg and 200mg therapy packs to guideline
- 2024-01-18: Removed OptumRx SP formulary and added OptumRx formulary instead
- 2024-01-03: New Program for Truqap
HEALTHY LIVING